Dendrimer-coupled sonophoresis-mediated transdermal drug-delivery system for diclofenac

Bin Huang¹
Wei-Jiang Dong²
Gao-Yi Yang³
Wei Wang¹
Cong-Hua Ji¹
Fei-Ni Zhou⁴
¹Department of Ultrasound, First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, ²Department of Ultrasonography, Tongxiang Chinese Medicine Hospital, Jiaxing, ³Department of Ultrasound, Hangzhou Red Cross Hospital, ⁴Department of Medical Records and Statistics, First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, People’s Republic of China

Abstract: The purpose of the present study was to develop a novel transdermal drug-delivery system comprising a polyamidoamine dendrimer coupled with sonophoresis to enhance the permeation of diclofenac (DF) through the skin. The novel transdermal drug-delivery system was developed by using a statistical Plackett–Burman design. Hairless male Wistar rat skin was used for the DF-permeation study. Coupling media concentration, ultrasound-application time, duty cycle, distance from probe to skin, and a third-generation polyamidoamine-dendrimer concentration were selected as independent variables, while in vitro drug release was selected as a dependent variable. Independent variables were found to be statistically significant (P<0.05). DF gel without dendrimer and ultrasound treatment to skin (passive delivery, run 13) showed 56.69 µg/cm² cumulative drug permeated through the skin, while the DF-dendrimer gel without sonophoresis treatment (run 14) showed 257.3 µg/cm² cumulative drug permeated through the skin after 24 hours. However, when the same gel was applied to sonophoresis-treated skin, drastic permeation enhancement was observed. In the case of run 3, the cumulative drug that permeated through the skin was 935.21 µg/cm². It was concluded that dendrimer-coupled sonophoresis-mediated transdermal drug delivery system has the potential to enhance the permeation of DF through the skin.

Keywords: sonophoresis, ultrasound, polyamidoamine, permeation enhancers, stratum corneum

Introduction

Diclofenac (DF) is a nonsteroidal anti-inflammatory drug. DF exhibits anti-inflammatory, analgesic, and antipyretic activities in animal models.¹–³ DF has been used effectively in symptomatic management of musculoskeletal disorders, arthritis, toothache, dysmenorrhea, etc, for symptomatic relief of pain and inflammation.⁴–⁷ DF sodium has a short half-life of 2 hours, making it necessary to administer the drug several times in a day. The drug undergoes substantial hepatic first-pass metabolism, and thus only about 50% of the administered dose reaches systemic circulation.⁸ The bioavailability of DF is 40%–60%, and it causes serious gastrointestinal (GI) adverse effects, including inflammation, bleeding, ulceration, and perforation of the stomach, small intestine, or large intestine, which can be fatal.⁹,¹⁰ With regard to all the drawbacks of oral delivery of DF, there is a need for an alternative route of administration that can bypass hepatic first-pass metabolism, avoid GI adverse effects, and improve bioavailability. The transdermal route of administration is an alternative choice for such drugs. This route is best suited for drugs that undergo first-pass metabolism with low bioavailability.¹¹,¹² Also, it avoids GI side effects, which increases patient compliance.¹³ However, the major limiting factor for the development of a transdermal drug-delivery system (TDDS) is the epidermal layer and others beneath the lining of the skin. These barriers are hurdles for the penetration of drugs.
Dendrimers are monodisperse, hyperbranched, three-dimensional, treelike macromolecules with host–guest entrapment properties. Dendrimers are a potent skin-permeation enhancer, as well as a solubility enhancer.\textsuperscript{14,15} Dendrimers are extensively used in pharmaceutical and biotechnological applications to deliver biomolecules.\textsuperscript{16} Dendrimers have been successfully utilized to improve the aqueous solubility of sulfamethoxazole, nadifloxacin, prulifloxacin, furosemide, ketoprofen, ibuprofen, diflunisal, albendazole, and ketoc吵nazole.\textsuperscript{17} Recently extensive work related to dendrimers has been carried out that includes the development of novel TDDSs with polyhydroxyalkanoate and starburst polyamidoamine (PAMAM) dendrimers.\textsuperscript{18} Dendrimer-mediated transdermal delivery enhances the bioavailability of indomethacin\textsuperscript{19} and the effect of polyamidoamine dendrimer on skin permeation of 5-fluorouracil.\textsuperscript{20}

Nowadays, apart from the use of permeation enhancers, ultrasound technology in the form of sonophoresis is used to deliver the active ingredient through the skin to achieve a more suitable therapeutic approach.\textsuperscript{21,22} In this technique, ultrasound is used to transfer the molecule through soft tissue as well as intact skin. It is one of the most promising novel DDDS, and has been shown to enhance the skin penetration and release rate of a number of drugs that have poor absorption or permeation profiles through the skin.\textsuperscript{23,24} This method is very rapid, convenient, and painless, functions independently of the drug’s electrical characteristics, and is useful for delivering low-molecular-weight drugs as well as macromolecules into skin.\textsuperscript{25} Many articles have summarized various aspects relating to sonophoresis, such as applications of sonophoresis and mechanisms and factors influencing sonophoresis in TDDSs. Enhanced skin permeation of DF by iontophoresis using this physical enhancement technique has been studied.\textsuperscript{26} Also, the effect of phonophoresis on skin permeation of the commercial anti-inflammatory gels sodium DF and ketoprofen was investigated.\textsuperscript{26} Sonophoresis-mediated transdermal and intradermal delivery for ketoprofen has been developed.\textsuperscript{27}

A TDDS comprising sonophoresis and potent skin permeation-enhancing dendrimer is yet to be studied. Such drug-delivery technology would be synergistic in terms of the permeation enhancement of the drug molecules through the skin. It has now been found that acoustic cavitation (formation of oscillation of microbubbles in the coupling medium) plays an important role in ultrasound-assisted delivery. The collapse of these microbubbles on the surface of the skin (stratum corneum [SC]) leads to skin permeation.\textsuperscript{28,29} Dendrimers are already a proven potential tool for skin-permeation enhancement for drug molecules. Due to the effect of sonophoresis on the skin, dendrimers lead to enhanced permeation of the drug through the skin. A TDDS is the potential technology for the transfer of active molecules through the skin.\textsuperscript{30,31} It serves as an alternative to an oral DDS. Transdermal delivery has certain advantages compared to the oral route. In particular, it is used when a drug has a significant first-pass effect as well as GI side effects.\textsuperscript{32,33} However, drug delivery through the skin is mainly limited by the SC, the topmost skin layer, which is composed of lipid-rich intercellular matrix and keratin-filled corneocytes.\textsuperscript{34,35} The lipid bilayer in the intercellular matrix is the major transport barrier for drug molecules.\textsuperscript{36,37} Drug molecules with molecular weight <500 Da and optimal physicochemical properties of log P 1–3 can be passively transported through the SC.\textsuperscript{38}

Due to such specific requirements of the physicochemical properties of the drug molecule, it becomes a challenge to the scientist to deliver the active molecule through the skin. Various chemical and physical enhancement strategies have been adapted for the successful delivery of active molecules through the skin. These include different chemicals as permeation enhancers that can alter the properties of the SC to make it more permeable to drug molecules. Various enhancement strategies, including prodrugs, terpenes, fatty acids, iontophoresis, sonophoresis, and laser ablation, have been used to increase the skin permeation of drug molecules.\textsuperscript{39–42} The aim of the present study was to develop a TDDS for DF using a PAMAM dendrimer as a permeation enhancer along with the use of sonophoresis to maximize the permeation of active molecules through the skin.

Materials and methods

Materials

DF was purchased from Shouguang Fukang Pharmacy (Shandong, People’s Republic of China [PRC]), and the third-generation PAMAM dendrimer (PAMAM G3) Carbopol 934 was purchased from Sigma-Aldrich (St Louis, MO, USA). Triethanolamine and other chemicals were purchased from Shanghai Chemical (Shanghai, PRC).

Methods

Experimental design

A Plackett–Burman design (PBD) is a two-level fractional factorial design. It enables the study of $k = N–1$ variables in N runs, when N is a multiple of 4. In this way, seven factors can be tested within seven runs, so the number of trials may be reduced down to an absolute minimum.\textsuperscript{43,44} The plan is dedicated to screening out numerous factors in order to choose the ones that mostly impact the process outcomes. Coupling media concentration (A), ultrasound application time (B), duty cycle (C), distance from probe to skin (D), and
PAMAM G3 dendrimer concentration (E) were selected as independent variables, while in vitro drug release (Y) was selected as a dependent variable. Different levels of dependent variables are shown in Table 1. The PBD was used to derive a second-order polynomial equation and construct contour plots to predict responses.

**Formulation of diclofenac dendrimer gel**

DF (200 mg) was dissolved in the required quantity of distilled water and PAMAM G3 dendrimer solution, as shown in Table 2, and was added to DF solution. In another 5 mL of distilled water, 100 mg Carbopol 934 was added and stirred with the help of a magnetic stirrer. DF in PAMAM G3 solution was added to Carbopol 934 gel, and the whole system was stirred with the help of a magnetic stirrer till a uniform homogeneous gel was formed. Triethanolamine was added dropwise during stirring to maintain the pH of the gel at 6.4. The gel was left for 48 hours to settle prior to use. This gel was used in each experiment. A control gel was also prepared without the addition of dendrimer to compare the effect of dendrimer on the skin permeation of DF.

**Animal skin preparation**

In this study, male Wistar rats (200–250 g) were used for the permeation study. These animals were housed in temperature-controlled rooms (23°C–25°C) with a full supply of water and diet. Hairless Wistar rats were killed using carbon dioxide asphyxiation. Abdominal skin was isolated, and subcutaneous fat adhering to the skin was removed carefully. A fresh defatted skin was used for each experiment. This experimental study was performed according to the ethical committee of the Zhejiang Chinese Medical University, and all the protocols were reviewed by the animal care and use committee.

**Sonophoresis experimental setup**

All the experiments were performed using low-frequency ultrasound of 20 kHz (VCX 130; Sonics and Materials, Newton, CT, USA) with tip diameter of 6 mm and probe length of 113 mm. The experimental setup was adjusted as described in Herwadkar et al.²⁷ Briefly, hairless abdominal skin was placed under the sonicator probe in such a way that the epidermal surface of the rat skin faced the sonicator probe. The distance between the probe and the skin was adjusted according to the experimental design. A glass donor chamber, open from both ends, of the vertical diffusion cell was placed over the skin. A coupling medium of sodium lauryl sulfate (SLS) with varying concentrations as per the experimental design was placed in the donor chamber. The sonicator probe was then placed in the coupling medium and ultrasound was activated for a predetermined time as per the experimental design. After ultrasound pretreatment, the skin was mounted on a Franz diffusion cell for permeation studies.

**In vitro permeation studies**

A specially designed glass diffusion cell was used to carry out an in vitro release study. Different ultrasound treatment conditions are shown in Table 2. An ultrasound-pretreated skin sample was mounted on the Franz diffusion cell in such a way that the epidermal surface of the skin faced toward the donor compartment of the cell. This skin was stretched around one end of the diffusion cell. The working surface area of the skin was 2.5 cm². The receptor compartment was filled with 20 mL pH 6.8 phosphate buffer (Office of Generic Drugs dissolution media in which the drug has maximum solubility compared to other dissolution media), and the temperature was maintained at 32°C±0.5°C with circulating hot water through a glass jacket. DF dendrimer gel 50 mg was placed on the skin. The receptor medium was stirred at 50 rpm by keeping it on a hot plate magnetic stirrer. Aliquots (5 mL) of

### Table 1 Variables and two levels

| Independent variable | Low level (-1) | High level (+1) |
|----------------------|---------------|----------------|
| A: SLS concentration | 1             | 2              |
| B: ultrasound application time | 1             | 3              |
| C: duty cycle | 50           | 100            |
| D: distance from probe to skin | 0.5           | 1              |
| E: dendrimer concentration | 0.3           | 0.5            |

**Notes:** Low level (−1) is the minimum concentration of independent variable used during the experiment; High level (+1) is the highest concentration of independent variable used during the experiment.

**Abbreviation:** SLS, sodium lauryl sulfate.

### Table 2 Formulation of diclofenac gel- and sonophoresis-treatment parameters

| Batch | Factor | Response | Y (µg/cm²) |
|-------|--------|----------|------------|
|       | A      | B        | C          | D         | E         |          |
| Run 1 | −1     | +1       | −1         | −1        | −1        | 435.68    |
| Run 2 | +1     | +1       | −1         | +1        | −1        | 478.96    |
| Run 3 | +1     | +1       | +1         | −1        | +1        | 935.21    |
| Run 4 | +1     | +1       | −1         | +1        | +1        | 727.7     |
| Run 5 | +1     | −1       | +1         | +1        | −1        | 580.45    |
| Run 6 | +1     | −1       | +1         | +1        | +1        | 550.00    |
| Run 7 | −1     | −1       | +1         | +1        | +1        | 650.00    |
| Run 8 | −1     | −1       | +1         | +1        | +1        | 792.60    |
| Run 9 | −1     | +1       | +1         | +1        | −1        | 620.78    |
| Run 10| −1     | +1       | +1         | +1        | +1        | 860.63    |
| Run 11| −1     | −1       | −1         | −1        | −1        | 320.85    |
| Run 12| +1     | −1       | −1         | −1        | +1        | 695.33    |

**Notes:** Factors A, B, C, D, E are independent variables. Y is the in vitro drug release through the skin.
Table 3 Diagnostic case statistics for various response variables

| Batch | Response variable | Actual value (µg/cm²) | Predicted value (µg/cm²) | Residual (F-test) |
|-------|-------------------|-----------------------|--------------------------|------------------|
| Run 1 | Y₁                | 435.68                | 436.07                   | -0.39            |
| Run 2 | Y₁                | 478.96                | 479.35                   | -0.39            |
| Run 3 | Y₁                | 935.21                | 935.01                   | 0.20             |
| Run 4 | Y₁                | 727.2                 | 727.00                   | 0.20             |
| Run 5 | Y₁                | 580.45                | 580.25                   | 0.20             |
| Run 6 | Y₁                | 550.00                | 549.80                   | 0.20             |
| Run 7 | Y₁                | 650.00                | 649.21                   | 0.79             |
| Run 8 | Y₁                | 792.60                | 793.58                   | -0.98            |
| Run 9 | Y₁                | 620.78                | 620.58                   | 0.20             |
| Run 10| Y₁                | 860.63                | 860.43                   | 0.20             |
| Run 11| Y₁                | 320.85                | 320.65                   | 0.20             |
| Run 12| Y₁                | 695.53                | 695.92                   | -0.39            |

Note: Values of F<0.05 indicate model terms are significant.

Table 4 Summary of results of regression analysis for responses (Y₁)

| Model                        | R²       | Adjusted R² | Predicted R² | SD      | PRESS   | CV     | Adequate precision |
|------------------------------|----------|-------------|--------------|---------|---------|--------|-------------------|
| Response (Y₁)                | 0.9857   | 0.9752      | 0.9969       | 1.52    | 1.08968 | 0.24   | 421.937           |
| Regression equation of the fitted model | Y₁ = +637.32+24.60A+47.33B+72.18C–0.67D+131.39E–5.17AB–22.85AD–4.99AE–5.20BD–3.10DE | |

Effect of dendrimer concentration

Dendrimers are potential skin-permeation enhancers. The potential of dendrimers as permeation enhancers has been
demonstrated by enhancing the permeation of 5-fluorouracil and indomethacin through the skin. In this experiment, further enhancement of the permeation potential of dendrimers using sonophoresis treatment was studied. From Figure 1B, it is clear that plain DF gel (without dendrimer) and without ultrasound treatment to skin (passive delivery) showed 56.69 µg/cm² cumulative drug permeated through the skin, while DF dendrimer gel without sonophoresis treatment (run 14) showed 257.3 µg/cm² cumulative drug permeated through the skin. This enhancement was 4.54-fold compared to plain DF gel. However, when the same gel was applied to sonophoresis-treated skin, drastic permeation enhancement was observed. In the case of run 3, the dendrimer concentration was 0.5 mL in gel, and cumulative drug permeated through the skin was 935.21 µg/cm². From this, it is clear that 16.5-fold permeation was enhanced when dendrimer was coupled with ultrasonic treatment to the skin.

From the contour plots (Figure 2A and B), it can be concluded that as the concentration of dendrimer increases, permeation through the skin also increases. The effect of dendrimer concentration on skin permeation was found to be statistically significant (P=0.0028). Also, Figure 2C shows the effect of one factor ie, dendrimer, on skin permeation of DF. From this, it is also clear that as the concentration of dendrimer increases, the skin permeation also increases. Permeation enhancers are small molecules that cause skin irritation or irreversibly alter the skin barrier to penetrate the skin in significant amounts. Among these permeation enhancers, dendrimers have proved to be a potential tool for enhanced delivery of drugs through the skin. Dendrimers have proved to be very potent chemicals in DDS. Earlier studies have shown that dendrimers increases the solubility of drugs in water through complexation with the surface functional groups and/or encapsulation within the dendrimer core.

### Table 5 Analysis of variance of models for \( Y_1 \)

| Source          | df | Sum of squares | Mean square | F-value | P-value |
|-----------------|----|----------------|-------------|---------|---------|
| Model for \( Y_1 \) | 10 | 3.514E+005     | 35,136.54   | 15,192.16 | 0.063   |
| A               |   | 5,234.99       | 5,234.99    | 2,263.48 | 0.0134  |
| B               |   | 15,932.33      | 15,932.33   | 6,888.74 | 0.0077  |
| C               |   | 32,064.35      | 32,064.35   | 13,863.83 | 0.0054  |
| D               |   | 3.91           | 3.91        | 1.69    | 0.4172  |
| E               |   | 1.237E+005     | 1.237E+005  | 53,500.99 | 0.0028  |
| AB              |   | 190.35         | 190.35      | 82.30   | 0.0699  |
| AD              |   | 3,480.97       | 3,480.97    | 1,505.08 | 0.0164  |
| AE              |   | 165.97         | 165.97      | 71.76   | 0.0748  |
| BD              |   | 180.41         | 180.41      | 78.00   | 0.0718  |
| DE              |   | 68.17          | 68.17       | 29.48   | 0.1160  |
| Residual        | 1  | 2.31           | 2.31        |         |         |
| Corrected total | 11 | 3.514E+005     |             |         |         |

**Figure 1** Comparative permeation enhancement effect of dendrimer on DF.

**Notes:** (A) Runs 1–12 represent the number-fold enhancements of permeation of diclofenac (DF) after ultrasonic treatment to skin at different conditions (run 3 shows maximum enhancement of 16.5-fold, while run 11 shows 5.5-fold enhancement). Run 14 shows the effect of dendrimer on untreated skin. (B) Comparative permeation enhancement of selected runs with plain DF gel. Run 3, run 4, run 8, and run 10 had maximum permeation-enhancement effects compared to other runs and plain DF gel.
Dendrimers are monodisperse hyperbranched polymers with a core–shell architecture containing a high density of tunable surface-functional groups. Dendrimers have a spherical architecture that provides a compact structure with a small hydrodynamic radius (1–10 nm) for transport across biological membranes. Due to these unique features, dendrimers have been widely investigated as drug and gene carriers by various routes of administration. Dendrimers act as a carrier and transport the drug in the solubilized form to the skin surface, from where it partitions into the SC, due to the high affinity of the lipophilic drug for skin lipids.

In earlier studies, dendrimer increased the permeation of drugs by increasing its water solubility through complexation with the surface functional groups and/or encapsulation within the dendrimer core. This permeation-enhancement effect was coupled with ultrasonic treatment on the skin that led to more permeation of DF through skin. Due to ultrasonic wave treatment through the coupling media, the medium absorbs the ultrasonic beam, which leads to a rise in temperature of the medium and causes a thermal effect. This thermal effect is responsible for the change in permeation behavior of the skin. All these events finally lead to permeation enhancement of active molecules through the skin.

**Effect of sodium lauryl sulfate on skin permeation**

During sonophoretic treatment of skin, SLS 1% and 2% was used as a coupling medium. It is an already proven fact that SLS enhances drug delivery several-fold when used alone. In this experiment, passive diffusion of DF from the gel (without dendrimer) was also tested without ultrasound treatment to the skin. In this case (run 13), 56.69 µg/cm² cumulative drug permeated through the skin during 24 hours. However, due to SLS treatment at varying concentrations, DF permeation through the skin was improved. The contour plots (Figure 2A and D, and Figure 3A) show the combined effect of SLS concentration and other factors on DF skin permeation. It was clear that as the concentration of SLS increased, the permeation-enhancement effect. This cavitation takes place through the creation of gaseous bubbles. After a few ultrasonic cycles, these bubbles get collapsed either inside or outside the skin. The transient bubbles get collapsed in the donor compartment to produce a shock wave with an amplitude of about 10 kbar, which perturbs the structure of the SC. All these events finally lead to permeation enhancement of active molecules through the skin.

![Diagram](https://example.com/diagram.jpg)

**Figure 2** Contour plots showing the effect of independent variables on skin permeation of DF.

**Notes:** (A) Combined effect of dendrimer and sodium lauryl sulfate (SLS) on skin permeation-enhancement effect of diclofenac (DF) through the skin. Both factors showed linear enhancement in permeation. (B) Combined effect of dendrimer and probe-to-skin distance on skin permeation-enhancement effect of DF through the skin. Both factors show linear enhancement in permeation. (C) Effect of single-factor dendrimer on skin permeation of DF. The effect was statistically significant ($P=0.0028$) on DF permeation through the skin. (D) Combined effect of SLS and probe-to-skin distance on skin permeation-enhancement effect of DF through the skin.
Skin permeation of DF also increased. The effect of SLS concentration (1% and 2%) was found to be statistically significant on DF skin permeation. Also, from Figure 3B, the same conclusion can be drawn, which shows the effect of a single factor on DF skin permeation. Iontophoretic fluxes of propranolol hydrochloride were effectively increased twofold in the SC pretreated with SLS. The use of SLS as a coupling media resulted in increases in dimensions of lacunar regions. It is also claimed that SLS is responsible for the increasing pore radii of sonophoresis-treated skin. Due to sonophoretic treatment, there may be chances of imperfections in the SC that led to increased DF skin permeation. Sonophoresis–SLS treatment leads to more consistent skin perturbation in comparison to sonophoresis treatment alone.

**Effect of ultrasound-application time**

It is a well-known fact that ultrasound treatment to skin causes the permeation enhancement of active molecules. This permeation intensity depends on the intensity, frequency, and application time of the ultrasound. In this experiment, the frequency was kept constant at 20 kHz. Before application of the gel, the skin was treated with ultrasound with a probe sonicator at different time periods. The aim was to find out the effect of ultrasound treatment on DF skin permeation. One experiment was also conducted without the application of ultrasound treatment to the skin. The effect of ultrasound-application time was studied at two different levels: −1 and +1. From Figure 3A and C, it is clear that as the ultrasound-application time increased, DF skin permeation also increased. Figure 3D shows the effect of a single factor (application time) on skin permeation. This clearly indicates that ultrasound treatment had a positive effect on the skin-permeation studies. Statistically, the effect of sonophoresis was found to be significant (P=0.0193). These results are similar with a study conducted on transdermal insulin.

**Effect of probe-to-skin distance**

To investigate the effect of probe-to-skin distance on DF permeation, the experiment was performed at two different levels (−1 and +1). In this experiment, the working distance was maintained at 0.5 cm and 1 cm between the skin and the probe. As the distance between the skin and the probe increased, the percentage drug release, ie, permeation of drugs, decreased. The same conclusion could be drawn from this experiment also. It can also be proved from Figure 4A (single-factor graph). From Figure 2B and D, and Figure 3D, it is clear that as the distance increased, the permeation effect decreased. However, this permeation-enhancement effect...
was not statistically significant ($P=0.4172$). It was found that generation of small holes and cavitation within the surface of the skin enhanced the permeation of active molecules through the skin. Increasing the distance between the probe and the skin reduced the cavitation effect on the skin, hence decreasing the permeability.

**Effect of duty cycle**

In this experiment, ultrasound was applied in pulsed (sequential) and continuous mode (100% duty cycle). Due to the application of ultrasound, a rise in temperature of coupling media occurs. This rise in temperature effect is faster and more intense with the continuous mode. Transdermal diffusion of prednisolone was increased in vitro by two- to fivefold with 1 MHz ultrasound at intensity 4.3 W/cm$^2$ in continuous mode.\(^5\) The pulsed mode is frequently used, because it reduces the severity of such side effects as thermal effects. Transdermal permeation of fentanyl was more effective with the pulsed mode of sonophoresis.\(^5\) In the present study also, similar results were observed. From Figure 4B, it is clear that DF skin permeation increased in the 100% duty cycle compared to the 50% duty cycle. The effect of duty cycle was found to be statistically significant ($P=0.0054$).

**Conclusion**

The present study reported a novel permeation-enhancement technique based on dendrimer-coupled sonophoresis for the transdermal drug delivery of DF. The TDDS was developed using a Plackett–Burman statistical design. The effect of all independent variables on permeation enhancement was found to be statistically significant. Dendrimer-coupled sonophoresis delivery increased DF permeation by 16.5-fold. From this study, it can be concluded that dendrimer-coupled sonophoresis is a novel technique to enhance the skin permeation of active molecules.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**

1. Nishihata T, Kamada A, Sakai K, et al. Percutaneous absorption of diclofenac in rats and humans: aqueous gel formulation. *Int J Pharm*. 1988;46:1–7.
2. Sharque KE, Al-Hamamy HM, Noaimib AA, Al-Shawi IA, Adil AN, Israa AA. Treatment of pityriasis versicolor using 1% diclofenac gel and clotrimazole cream (comparative therapeutic study). *J Saudi Soc Dermatol Dermatol Surg*. 2011;15:19–23.
3. Asasutjarit R, Thanasanokpibull S, Fuongfuchat A, Veeranondha S. Evaluation of optimization and evaluation of thermosteresive diclofenac sodium ophthalmic in situ gels. *Int J Pharm*. 2011;411:128–135.
4. Dugowson CE, Gnanashanmugam P. Nonsteroidal anti-inflammatory drugs. *Phys Med Rehabil Clin N Am*. 2006;17:347–354.
5. Chan FK, Hung LC, Suen BY, et al. Celecoxib versus diclofenac plus omeprazole in high risk arthritis patients: results of a randomized double-blind trial. *Gastroenterology*. 2004;127:1038–1043.
6. Wong VW, Chan FK. Review: Misoprostol or COX-2-specific or selective NSAIDs reduce gastrointestinal complications and symptomatic ulcers. *ACP J Club*. 2005;142:75.
7. O’Neil MJ, Heckelman PE, Koch CB, Roman KJ, Kenny CM, D’Arecca MR. The transdermal delivery of zwitterion salts. *Drug Deliv*. 2011;15:19–23.
8. US Food and Drug Administration. Diclofenac [prescribing information]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021005s013lbl.pdf. Accessed March 03, 2015.
9. Rostom A, Dubé C, Wells G, et al. Prevention of NSAID-induced gastrointestinal ulcers. *Cochrane Database Syst Rev*. 2002; (4):CD002296.
10. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. *JAMA*. 2008;299:2031–2041.
11. Neese DM, Eif SF, Ei-Houseny SS. Development of novel transdermal self-adhesive films for tenoxicam, an anti-inflammatory drug. *Life Sci*. 2011;89:430–438.
12. Khurana S, Jain NK, Bedi PM. Development and characterization of a novel controlled release drug delivery system based on nanostructured lipid carriers gel for meloxicam. *Life Sci*. 2013;93:763–772.
13. Mazzenga GC, Berner B. The transdermal delivery of zwitterionic drugs I: the solubility of zwitterion salts. *J Control Release*. 1991;16:77–88.
14. Ma M, Cheng Y, Xu Z, et al. Evaluation of polyamidoamine (PAMAM) dendrimers as drug carriers of anti-bacterial drugs using sulfamethoxazole (SMZ) as a model drug. *J Med Chem*. 2007;42:93–98.

15. Bosnjakovic A, Mishra MK, Ren W, et al. Poly(amidoamine) dendrimer-erythromycin conjugates for drug delivery to macrophages involved in periprosthetic inflammation. *Nanomedicine*. 2011;7:284–294.

16. Choksi A, Sarojini KV, Vadnal P, Dias C, Suresh PK, Khandare J. Comparative anti-inflammatory activity of poly(amidoamine) (PAMAM) dendrimer-dexamethasone conjugates with dexamethasone-liposomes. *Int J Pharm*. 2013;449:28–36.

17. Gupta U, Agashe HB, Asthana A, Jain NK, Dendrimers: novel polymeric nanoarchitectures for solubility enhancement. *Biomacromolecules*. 2006;7:649–658.

18. Wang Z, Itoh Y, Hosaka Y, et al. Novel transdermal drug delivery system with polyhydroxyalkanoate and starburst polyamidoamine dendrimer. *J Biosci Bioeng*. 2003;95:541–543.

19. Chauhan AS, Sridevi S, Chalasani KB, et al. Dendrimer-mediated transdermal delivery: enhanced bioavailability of indomethacin. *J Control Release*. 2003;90:335–343.

20. Venuganti VV, Perumal OP. Effect of poly(amidoamine) (PAMAM) dendrimer on skin permeation of 5-fluorouracil. *Int J Pharm*. 2008;361:230–238.

21. Vargese EA, Khar RK. Enhanced skin permeation of diclofenac sodium by iontophoresis: in vitro and in vivo studies. *J Control Release*. 1996;38:21–27.

22. Motta AF, Borges NG Jr, da Fonseca JC, Tonussi CR. The antiinociceptive effect of iontophoretic direct application of diclofenac to arthritic knee-joints of rats. *Life Sci*. 2003;73:1995–2004.

23. Polat BE, Figueroa PL, Blankschtein D, Langer R. Transport pathways and enhancement mechanisms within localized and non-localized transport regions in skin treated with low-frequency sonophoresis and sodium lauryl sulfate. *J Pharm Sci*. 2011;100:512–529.

24. Polat BE, Hart D, Langer R, Blankschtein D. Ultrasound-mediated transdermal drug delivery: mechanisms, scope, and emerging trends. *J Control Release*. 2011;152:330–348.

25. Tang H, Wang CC, Blankschtein D, Langer R. An investigation of the role of cavitation in low-frequency ultrasound-mediated transdermal drug transport. *Pharm Res*. 2002;19:1160–1169.

26. Souza J, Meira A, Volpato NM, Mayorga P, Gottfried C. Effect of phonophoresis on skin permeation of commercial anti-inflammatory gels: sodium diclofenac and ketoprofen. *Ultrason Med Biol*. 2013;39:1623–1630.

27. Hervadkar A, Sachdev V, Taylor LF, Silver H, Banga AK. Low frequency sonophoresis mediated transdermal and intradermal delivery of ketoprofen. *Int J Pharm*. 2012;423:289–296.

28. Ueda H, Mutoh M, Seki T, Kobayashi D, Morimoto Y. Acoustic caviation as an enhancing mechanism of low-frequency sonophoresis for transdermal drug delivery. *Bioll Pharm Bull*. 2009;32:916–920.

29. Ueda H, Sugiyayashi K, Morimoto Y. Skin penetration-enhancing effect of drugs by phonophoresis. *J Control Release*. 1995;37:291–297.

30. Osborne JL, Sanchez IC, Paul DR. An asymptotic analysis of drug delivery from transdermal patches. *J Membr Sci*. 2013;442:27–30.

31. Kim MH, Park DH, Yang JH, Choy YB, Choy JH. Drug-inorganic-polymer nanohybrid for transdermal delivery. *Int J Pharm*. 2013;444:120–127.

32. Mura P, Bragagn M, Mennini N, Cirri M, Maestrelli F. Development of liposomal and microemulsion formulations for transdermal delivery of clonazepam: effect of randomly methylated β-cyclodextrin. *Int J Pharm*. 2014;475:306–314.

33. Delgado-Chorro MB, Guy RH. Effective use of transdermal drug delivery in children. *Adv Drug Deliv Rev*. 2014;73:63–82.

34. Alexander A, Dwivedi S, Ajazuddin M, et al. Approaches for breaking the barriers of drug permeation through transdermal drug delivery. *J Control Release*. 2012;164:26–40.

35. El-Nabarawi MA, Bendas ER, El Rehem RT, Abary MY. Transdermal drug delivery of paroxetine through lipid-vascular formulation to augment its bioavailability. *Int J Pharm*. 2013;443:307–317.
